# Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

> **NCT02089737** · — · COMPLETED · sponsor: **Takeda** · enrollment: 3091 (actual)

## Conditions studied

- Advanced or Recurrent Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT02089737
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 3091 (ACTUAL)
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089737, "Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02089737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*